CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium
January 11 2024 - 4:05PM
Business Wire
CareDx Symposium to Highlight New Real-World
Use Cases Using its Testing and Digital Solutions for Improved
Patient Risk Management
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on
the discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers – today announced a leading presence and
the fifth consecutive year as the Distinguished Founder’s Circle
Sponsor for the Annual American Society of Transplant Surgeons
(ASTS) Winter Symposium being held January 11 - 14, 2024 in Miami,
Florida.
CareDx and research collaborators are sharing the latest
clinical advances to help advance transplant patient care using
CareDx’s non-invasive testing services and digital health solutions
at the meeting.
“As a longtime supporter of ASTS, we are honored to continue our
commitment as the Founder's Circle Sponsor. It is gratifying to
witness the clinical use of our non-invasive molecular diagnostics,
predictive modeling, and digital health tools make a tangible
impact in advancing transplant patient care,” said Robert Woodward,
PhD, Chief Scientific Officer at CareDx. “The real-world impact
showcased in the presented case studies underscores our commitment
to transforming transplant patient care for improved long-term
outcomes.”
During its industry sponsored symposium, titled, “Real-World Use
of AlloSure® in Identifying, Stratifying, and Mitigating Risk to
Optimize Transplant Outcomes,” leading transplant experts will
demonstrate how CareDx's molecular testing services, digital
solutions, and risk assessment tools can improve access and
outcomes within transplantation. The following speakers will also
discuss the integration of these technologies into clinical
practice and means for future development.
- Irene Kim, MD, FACS, Professor & Chair, Department of
Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical
Center
- Matthew Cooper, MD, Chief of Division of Transplant Surgery,
Director of the Solid Organ Transplant Service Line, Froedtert
Memorial Lutheran Hospital and Children's Wisconsin
“I'm pleased to be part of CareDx's symposium to demonstrate how
non-invasive molecular diagnostics and digital tools can provide
new insights in managing high risk patients,” said Dr. Matthew
Cooper. “I'll share how we utilize AlloSure to monitor and manage
patients with delayed graft function, along with patient case
examples showcasing our use of these innovative technologies to
demonstrate their real-world impact on patient care.”
CareDx AlloSure data will also be featured in a presentation
being delivered at the ASTS Research Grants session in a talk
titled, “Using Phenotypic Precision Medicine to Individualize
Immunosuppression Based on Quantifiable Markers of Immune Response
and Allograft Injury.”
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California is a leading
precision medicine solutions company focused on the discovery,
development, and commercialization of clinically differentiated,
high-value healthcare solutions for transplant patients and
caregivers. CareDx offers testing services, products, and digital
healthcare solutions along the pre- and post-transplant patient
journey and is the leading provider of genomics-based information
for transplant patients. For more information, please visit:
www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the potential
benefits and results that may be achieved with CareDx’s digital
health solutions in kidney, heart, and lung transplant patients,
including AlloSure, and its sponsorship of and participation at the
2024 ASTS Winter Symposium. These forward-looking statements are
based upon information that is currently available to CareDx and
its current expectations, speak only as of the date hereof, and are
subject to risks and uncertainties that could cause actual results
to differ materially from those projected, including risks that
CareDx does not realize the expected benefits of its digital health
solutions including AlloSure, or its sponsorship and participation
of the 2024 ASTS Winter Symposium; general economic and market
factors; and other risks discussed in CareDx’s filings with the
SEC, including the Annual Report on Form 10-K for the fiscal year
ended December 31, 2022 filed by CareDx with the SEC on February
27, 2023, the quarterly report on Form 10-Q for the quarter ended
March 31, 2023 filed by CareDx with the SEC on May 10, 2023, the
quarterly report on Form 10-Q for the quarter ended June 30, 2023
filed by CareDx with the SEC on August 8, 2023, the quarterly
report on Form 10-Q for the quarter ended September 30, 2023 filed
by CareDx with the SEC on or about November 8, 2023, and other
reports that CareDx has filed with the SEC. Any of these may cause
CareDx’s actual results, performance, or achievements to differ
materially and adversely from those anticipated or implied by
CareDx’s forward-looking statements. CareDx expressly disclaims any
obligation, except as required by law, or undertaking to update or
revise any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240111139097/en/
CareDx, Inc. Media Relations Anna Czene 818-731-2203
aczene@caredx.com
Investor Relations Greg Chodaczek investor@caredx.com
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Apr 2023 to Apr 2024